Glyoka-VM1 Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 1 mg, Metformin 500 mg, and Voglibose 0.2 mg, each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, thereby reducing insulin resistance. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, mitigating postprandial hyperglycemia. The sustained-release formulation ensures gradual drug release, promoting consistent plasma concentrations and improved patient compliance. Glyoka-VM1 is indicated as adjunctive therapy to diet and exercise for patients inadequately controlled on monotherapy or dual therapy. It should be used cautiously in patients with renal or hepatic impairment and is contraindicated in conditions such as diabetic ketoacidosis, severe renal dysfunction, or hypersensitivity to any component. Regular monitoring of blood glucose, renal function, and potential adverse effects like hypoglycemia, gastrointestinal disturbances, and lactic acidosis is recommended. Glyoka-VM1 Tablet SR offers a comprehensive approach to glycemic management by targeting multiple pathophysiological defects in type 2 diabetes.